Senores Pharmaceuticals share price
NSE: SENORESBSE: 544319Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,215.30up ₹12.70 (1.06%)BSE ₹1,213.90
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,202.60.
52-week range of traded prices to 23 Oct 2026
₹706.00Low, 23 Mar 2026₹1,599.00High, 24 Aug 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,597 Cr841st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 27 Jul 2026
- 42.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 6.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 27 Jul 2026
- 15.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 27 Jul 2026
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.34
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,65,74443.3% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 27 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹180 Crup 2.87%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹30 Crdown 16.96%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 16.9%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2026, the company's revenue for that year, ₹633 Cr, differs from its quarters added, ₹650 Cr.
| ₹ crore | Dec 2024Filed 24 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 24 Jul | Sep 2025Filed 6 Nov | Dec 2025Filed 20 Jan | Mar 2026Filed 27 May | Jun 2026Filed 27 Jul |
|---|---|---|---|---|---|---|---|
| Revenue | 103 | 114 | 138 | 162 | 175 | 175 | 180 |
| Net profit | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 15.9% | 15.7% | 15.3% | 18.6% | 19.2% | 20.9% | 16.9% |
Consolidated. The 7 quarters from Dec 2024, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
The quarters either side of a change of basis do not compare. From the quarter to Mar 2026, the company's revenue for the year to Mar 2026, ₹633 Cr, differs from its quarters added, ₹650 Cr.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the year to Mar 2026: days before it are of the company before the change.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 47% of 238 trading days since Nov 2025.
LowestHighest
Its median43.1Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 64% of 247 trading days over the last year.
LowestHighest
Its median5.1Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.28.2
At or below today's level on 38% of 238 trading days since Nov 2025.
LowestHighest
Its median29.1Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +33.1% | +63.7% | −18.7% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual funds holding it
27 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 6 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 8
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 1
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
| Fund | |||
|---|---|---|---|
 HSBC Small Cap FundHSBC Mutual Fund | 4,94,440 | 0.37% | ₹68.5 Cr |
| HSBC Value FundHSBC Mutual Fund | 4,35,124 | 0.41% | ₹60.3 Cr |
 Mahindra Manulife Large & Mid Cap FundMahindra Manulife Mutual Fund | 4,29,600 | 2.16% | ₹59.5 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 4,03,526 | 0.66% | ₹55.9 Cr |
 Trustmf Small Cap FundTrust Mutual Fund | 3,46,668 | 1.24% | ₹48.0 Cr |
| HSBC Multi Cap FundHSBC Mutual Fund | 2,86,063 | 0.62% | ₹39.6 Cr |
| Bajaj Finserv Small Cap FundBajaj Finserv Mutual Fund | 2,19,483 | 1.10% | ₹30.4 Cr |
| Bajaj Finserv Multi Asset Allocation FundBajaj Finserv Mutual Fund | 1,13,314 | 0.82% | ₹15.7 Cr |
| HSBC India Export Opportunities FundHSBC Mutual Fund | 1,03,910 | 1.11% | ₹14.4 Cr |
| Mahindra Manulife Balanced Advantage FundMahindra Manulife Mutual Fund | 90,000 | 1.42% | ₹12.5 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Senores Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Bliss GVS PharmaBLISSGVS | 6,628 | 48.7 | 5.6 | 34.5 | +20.6% | +27.7% | 12.1% | 12.3% | 0.24% |
 Supriya LifescienceSUPRIYA | 6,588 | 33.2 | 5.5 | 22.5 | +28.1% | +11.4% | 18.1% | 21.6% | 0.12% |
 Sanofi IndiaSANOFI | 6,386 | 19.7 | 7.7 | 12.5 | −8.9% | −10.7% | 40.3% | 54.0% | 4.44% |
 Innova CaptabINNOVACAP | 5,650 | 36.1 | 5.2 | 23.1 | +34.5% | +20.4% | 15.3% | 15.0% | 0.20% |
 Sun Pharma Advanced Research CompanySPARC | 5,574 | 3.5 | 4.2 | 3.8 | +2,855.8% | – | 118.4% | 84.8% | 0.00% |
 FDCFDC | 5,514 | 18.8 | 2.2 | 16.3 | +3.4% | +8.7% | 12.3% | 11.1% | 1.48% |
 Orchid PharmaORCHPHARMA | 4,930 | – | – | – | +26.2% | – | – | 0.2% | 0.00% |
 IOL Chemicals and PharmaceuticalsIOLCP | 4,818 | 28.7 | 2.7 | 15.3 | +18.6% | +60.1% | 9.6% | 11.8% | 0.61% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
23 Oct · Analysts
22 Oct · Analysts
16 Oct · Meeting
Sep 2026
Senores Pharmaceuticals share price by year
Each calendar year to 2025.Senores Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 822.20 | +44.6% | 827.65 | 444.30 |
| 2024 | 568.60 | – | 568.60 | 557.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 30 Dec 2024.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,210.80 | 1,220.60 | 1,168.10 | 1,215.30 | 1,199.55 | 1,65,744 | 43.3% |
| 22 Oct 2026 | 1,202.10 | 1,242.60 | 1,195.00 | 1,202.60 | 1,214.19 | 1,82,678 | 45.8% |
| 21 Oct 2026 | 1,253.60 | 1,255.20 | 1,196.00 | 1,224.10 | 1,219.83 | 3,03,198 | 54.5% |
| 19 Oct 2026 | 1,323.60 | 1,345.00 | 1,241.30 | 1,253.60 | 1,289.73 | 2,49,045 | 45.3% |
| 16 Oct 2026 | 1,258.80 | 1,324.40 | 1,253.60 | 1,318.40 | 1,294.14 | 2,86,388 | 43.4% |
| 15 Oct 2026 | 1,281.00 | 1,297.40 | 1,254.00 | 1,258.80 | 1,271.37 | 1,59,308 | 40.3% |
| 14 Oct 2026 | 1,321.00 | 1,325.30 | 1,271.00 | 1,281.50 | 1,291.53 | 1,45,695 | 60.8% |
| 13 Oct 2026 | 1,318.70 | 1,332.00 | 1,286.60 | 1,321.00 | 1,305.16 | 1,68,254 | 46.5% |
| 12 Oct 2026 | 1,335.10 | 1,349.00 | 1,311.00 | 1,318.70 | 1,327.06 | 1,30,501 | 43.8% |
| 9 Oct 2026 | 1,328.80 | 1,344.40 | 1,306.30 | 1,320.00 | 1,321.33 | 1,41,415 | 40.1% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Senores Pharmaceuticals Limited
- NSE symbol
- SENORES
- BSE code
- 544319
- ISIN
- INE0RB801010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 2024
- Face value
- ₹10
- CIN
- L24290GJ2017PLC100263
- Corporate identity number, the registrar of companies' code for it